Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV – Get Rating) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $3.62 and traded as high as $5.05. Achieve Life Sciences shares last traded at $4.85, with a volume of 65,692 shares traded.
Analyst Ratings Changes
Several research firms recently weighed in on ACHV. Maxim Group dropped their price objective on shares of Achieve Life Sciences from $21.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, November 16th. Oppenheimer dropped their price objective on shares of Achieve Life Sciences from $27.00 to $20.00 in a research report on Tuesday, November 15th.
Achieve Life Sciences Stock Down 1.8 %
The firm’s 50-day simple moving average is $3.17 and its 200 day simple moving average is $3.62. The company has a market cap of $86.82 million, a P/E ratio of -1.22 and a beta of 1.22. The company has a debt-to-equity ratio of 15.10, a quick ratio of 3.03 and a current ratio of 3.03.
Achieve Life Sciences (NASDAQ:ACHV – Get Rating) last issued its earnings results on Monday, November 14th. The biopharmaceutical company reported ($1.35) EPS for the quarter, missing the consensus estimate of ($1.10) by ($0.25). On average, research analysts forecast that Achieve Life Sciences, Inc. will post -4.04 earnings per share for the current fiscal year.
Institutional Trading of Achieve Life Sciences
Several institutional investors and hedge funds have recently made changes to their positions in ACHV. Raymond James & Associates bought a new stake in shares of Achieve Life Sciences during the 1st quarter valued at $99,000. Charles Schwab Investment Management Inc. acquired a new position in shares of Achieve Life Sciences in the 1st quarter valued at $79,000. State Street Corp grew its holdings in shares of Achieve Life Sciences by 26.9% in the 1st quarter. State Street Corp now owns 18,731 shares of the biopharmaceutical company’s stock valued at $142,000 after buying an additional 3,970 shares during the period. Perkins Capital Management Inc. grew its holdings in shares of Achieve Life Sciences by 30.6% in the 2nd quarter. Perkins Capital Management Inc. now owns 228,100 shares of the biopharmaceutical company’s stock valued at $1,113,000 after buying an additional 53,500 shares during the period. Finally, Granite Point Capital Management L.P. acquired a new position in shares of Achieve Life Sciences in the 2nd quarter valued at $67,000. Institutional investors own 21.11% of the company’s stock.
About Achieve Life Sciences
Achieve Life Sciences, Inc is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
Read More
Receive News & Ratings for Achieve Life Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Achieve Life Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.